Bortezomib in relapsed/refractory immune thrombotic thrombocytopenic purpura: A single‐centre retrospective cohort and systematic literature review

Daratumumab for refractory immune‐mediated thrombotic thrombocytopenic purpura

(2023) Asha Aggarwal et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bortezomib, a promising alternative for patients with refractory or relapsed thrombotic thrombocytopenic purpura after rituximab treatment

(2022) Jie Yin et al.   BRITISH JOURNAL OF HAEMATOLOGY

REDEFINING OUTCOMES IN IMMUNE TTP: AN INTERNATIONAL WORKING GROUP CONSENSUS REPORT

(2021) Adam Cuker et al.   BLOOD

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

(2021) Matthew J Page et al.   BMJ-British Medical Journal

Major adverse cardiovascular events in survivors of immune‐mediated thrombotic thrombocytopenic purpura

(2021) Max A. Brodsky et al.   AMERICAN JOURNAL OF HEMATOLOGY

Complete ADAMTS13 remission in a patient with refractory autoimmune-mediated thrombotic thrombocytopenic purpura after infliximab

(2021) Natalie Bavli et al.   TRANSFUSION AND APHERESIS SCIENCE

Cardiovascular Disease is a Leading Cause of Mortality among TTP Survivors in Clinical Remission

(2021) Senthil Sukumar et al.   Blood Advances

Daratumumab for immune thrombotic thrombocytopenic purpura

(2021) Jana Van den Berg et al.   Blood Advances

Low levels of ADAMTS ‐13 with high anti‐ADAMTS ‐13 antibodies during remission of immune‐mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi‐institutional study

(2020) Francesca Schieppati et al.   AMERICAN JOURNAL OF HEMATOLOGY

Successful Treatment With Bortezomib for Refractory and Complicated Acquired Thrombotic Thrombocytopenic Purpura in an Adolescent Girl

(2020) Ebru Azapağasi et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Bortezomib induces long‐term remission in children with immune thrombotic thrombocytopenic purpura, refractory to plasma exchange, glucocorticoids, and rituximab: A report on two cases

(2020) Alexey Maschan et al.   PEDIATRIC BLOOD & CANCER

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

(2019) Marie Scully et al.   NEW ENGLAND JOURNAL OF MEDICINE

Refractory Thrombotic Thrombocytopenic Purpura in a patient with Kaposi sarcoma

(2019) Osman Sahin et al.   TRANSFUSION AND APHERESIS SCIENCE

Comparison of the Long-Term Remission of Rituximab and Conventional Treatment for Acquired Thrombotic Thrombocytopenic Purpura: A Systematic Review and Meta-Analysis

(2019) Weerapat Owattanapanich et al.   CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS

Survival of a Jehovah's Witness with thrombotic thrombocytopenic purpura without using plasma: A case report and review of the literature

(2019) Babak Baseri et al.   JOURNAL OF CLINICAL APHERESIS

Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors

(2019) Harshvardhan Upreti et al.   BLOOD

Relapsed/refractory acquired thrombotic thrombocytopenic purpura in a patient with Sjögren syndrome

(2018) Rurong Sun et al.   MEDICINE

Therapeutic plasma exchange for thrombotic thrombocytopenic purpura with refractory thrombocytopenia

(2017) Nolan Maloney et al.   JOURNAL OF CLINICAL APHERESIS

Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies

(2017) M. Scully et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura

(2016) Christopher J. Patriquin et al.   BRITISH JOURNAL OF HAEMATOLOGY

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

(2016) Flora Peyvandi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib

(2016) Priyank P. Patel et al.   TRANSFUSION

How I treat refractory thrombotic thrombocytopenic purpura

(2015) Farzana A. Sayani et al.   BLOOD

Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report

(2014) Sean Yates et al.   TRANSFUSION

Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP)

(2013) Neil Shah et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura

(2013) Marshall A. Mazepa et al.   BRITISH JOURNAL OF HAEMATOLOGY

Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib

(2013) Tessa van Balen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

ADAMTS13 Antibody Depletion by Bortezomib in Thrombotic Thrombocytopenic Purpura

(2013) Jake Shortt et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura

(2011) M. Scully et al.   BLOOD

Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse

(2008) Ming Jin et al.   BRITISH JOURNAL OF HAEMATOLOGY